Back to top
more

Progyny (PGNY)

(Delayed Data from NSDQ)

$32.54 USD

32.54
546,094

+0.50 (1.56%)

Updated Apr 29, 2024 03:59 PM ET

After-Market: $32.54 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 51.47% and 25.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Progyny (PGNY) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Earnings Preview: Charles River Laboratories (CRL) Q3 Earnings Expected to Decline

by Zacks Equity Research

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Progyny (PGNY) Q3 Earnings Expected to Decline

by Zacks Equity Research

Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Buy Stocks for October 30th

by Zacks Equity Research

CVEO, FBP, EIG, MNTX and PGNY have been added to the Zacks Rank #1 (Strong Buy) List on October 30, 2023.

New Strong Buy Stocks for October 17th

by Zacks Equity Research

MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.

Humana (HUM) Boosts Healthcare Choices for MA Members in Denver

by Zacks Equity Research

Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.

Indrajit Bandyopadhyay headshot

4 Undervalued Medical Stocks to Buy Amid High Market Volatility

by Indrajit Bandyopadhyay

Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.

3 Reasons Growth Investors Will Love Progyny (PGNY)

by Zacks Equity Research

Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Acadia Healthcare (ACHC) Up 11% in 3 Months: More Room to Run?

by Zacks Equity Research

Acadia Healthcare (ACHC) is well-poised for growth on an expansive healthcare portfolio, which in turn, boosts its patient volumes.

Here is Why Growth Investors Should Buy Progyny (PGNY) Now

by Zacks Equity Research

Progyny (PGNY) could produce exceptional returns because of its solid growth attributes.

Progyny (PGNY) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Compared to Estimates, Progyny (PGNY) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Progyny (PGNY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Progyny (PGNY) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 50% and 6.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?

by Zacks Equity Research

Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

MD vs. PGNY: Which Stock Is the Better Value Option?

by Zacks Equity Research

MD vs. PGNY: Which Stock Is the Better Value Option?

What Makes Progyny (PGNY) a New Buy Stock

by Zacks Equity Research

Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Should You Buy Progyny (PGNY) After Golden Cross?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Looking for a Growth Stock? 3 Reasons Why Progyny (PGNY) is a Solid Choice

by Zacks Equity Research

Progyny (PGNY) possesses solid growth attributes, which could help it handily outperform the market.

Earnings Estimates Moving Higher for Progyny (PGNY): Time to Buy?

by Zacks Equity Research

Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

How Much Upside is Left in Progyny (PGNY)? Wall Street Analysts Think 32.32%

by Zacks Equity Research

The consensus price target hints at a 32.3% upside potential for Progyny (PGNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Progyny (PGNY) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 125% and 5.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Progyny (PGNY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 50% and 1.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Premier, Inc. (PINC) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 7.46% and 0.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.